Literature DB >> 21720261

Concurrent primary aldosteronism and subclinical cortisol hypersecretion: a prospective study.

Francesco Fallo1, Chiara Bertello, Davide Tizzani, Ambrogio Fassina, Sheerazed Boulkroun, Nicoletta Sonino, Silvia Monticone, Andrea Viola, Franco Veglio, Paolo Mulatero.   

Abstract

BACKGROUND: Primary aldosteronism is the most frequent cause of secondary hypertension and is responsible for an increased risk of cardiometabolic complications. A concomitant subtle cortisol hyperproduction could enhance cardiovascular risk. We prospectively estimated the occurrence of subclinical hypercortisolism in primary aldosteronism patients.
METHODS: In a large population of hypertensive patients without clinical signs of hypercortisolism, 76 consecutive patients with primary aldosteronism were investigated. Differential diagnosis between unilateral and bilateral aldosterone hypersecretion was made by computed tomography/MRI and/or adrenal venous sampling (AVS). Subclinical hypercortisolism was defined as failure to suppress plasma cortisol to less than 50 nmol/l after 1 mg-overnight dexamethasone, used as screening test, and at least one of two other abnormal hormonal parameters, that is, adrenocorticotrophin (ACTH) less than 2 pmol/l and urinary cortisol more than 694 nmol/24 h.
RESULTS: Three out of 76 patients had postdexamethasone plasma cortisol more than 50 nmol/l. Only one also showed low-normal ACTH and mildly elevated urinary cortisol. The patient had a right 4 cm adrenal mass. Laparoscopic adrenalectomy was followed by short-term steroid replacement to prevent adrenal insufficiency. In-situ hybridization showed CYP11B1 expression exclusively in tumoral tissue, whereas CYP11B2 was expressed only in a peritumoral region composed of zona glomerulosa-like cells, suggesting the co-existence of a cortisol-producing adenoma and an aldosterone-producing hyperplasia in the same adrenal. The restoration of hormone abnormalities to normal levels was confirmed at 12 months of follow-up.
CONCLUSION: Concurrent aldosterone and subclinical cortisol hypersecretion seems to be a rare event in primary aldosteronism patients; however, its detection by appropriate testing is important to avoid AVS misinterpretation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21720261     DOI: 10.1097/HJH.0b013e32834937f3

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  14 in total

1.  Histopathological and genetic characterization of aldosterone-producing adenomas with concurrent subclinical cortisol hypersecretion: a case series.

Authors:  Francesco Fallo; Isabella Castellano; Celso E Gomez-Sanchez; Yara Rhayem; Catia Pilon; Valentina Vicennati; Donatella Santini; Valeria Maffeis; Ambrogio Fassina; Paolo Mulatero; Felix Beuschlein; Martin Reincke
Journal:  Endocrine       Date:  2017-04-12       Impact factor: 3.633

Review 2.  Issues in the Diagnosis and Treatment of Primary Aldosteronism.

Authors:  Jacopo Burrello; Silvia Monticone; Fabrizio Buffolo; Martina Tetti; Giuseppe Giraudo; Domenica Schiavone; Franco Veglio; Paolo Mulatero
Journal:  High Blood Press Cardiovasc Prev       Date:  2015-04-09

3.  Measurement of peripheral plasma 18-oxocortisol can discriminate unilateral adenoma from bilateral diseases in patients with primary aldosteronism.

Authors:  Fumitoshi Satoh; Ryo Morimoto; Yoshikiyo Ono; Yoshitsugu Iwakura; Kei Omata; Masataka Kudo; Kei Takase; Kazumasa Seiji; Hidehiko Sasamoto; Seijiro Honma; Mitsunobu Okuyama; Kouwa Yamashita; Celso E Gomez-Sanchez; William E Rainey; Yoichi Arai; Hironobu Sasano; Yasuhiro Nakamura; Sadayoshi Ito
Journal:  Hypertension       Date:  2015-03-16       Impact factor: 10.190

4.  ARMC5 mutation analysis in patients with primary aldosteronism and bilateral adrenal lesions.

Authors:  P Mulatero; F Schiavi; T A Williams; S Monticone; G Barbon; G Opocher; F Fallo
Journal:  J Hum Hypertens       Date:  2015-10-08       Impact factor: 3.012

5.  Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas.

Authors:  Silvia Monticone; Isabella Castellano; Karine Versace; Barbara Lucatello; Franco Veglio; Celso E Gomez-Sanchez; Tracy A Williams; Paolo Mulatero
Journal:  Mol Cell Endocrinol       Date:  2015-05-06       Impact factor: 4.102

6.  Benign adrenal adenomas secreting excess mineralocorticoids and glucocorticoids.

Authors:  Vivienne Yoon; Aliya Heyliger; Takashi Maekawa; Hironobu Sasano; Kelley Carrick; Stacey Woodruff; Jennifer Rabaglia; Richard J Auchus; Hans K Ghayee
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2013-09-23

Review 7.  New Advances in the Diagnostic Workup of Primary Aldosteronism.

Authors:  Martin J Wolley; Michael Stowasser
Journal:  J Endocr Soc       Date:  2017-01-27

8.  Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism.

Authors:  Wiebke Arlt; Katharina Lang; Alice J Sitch; Anna S Dietz; Yara Rhayem; Irina Bancos; Annette Feuchtinger; Vasileios Chortis; Lorna C Gilligan; Philippe Ludwig; Anna Riester; Evelyn Asbach; Beverly A Hughes; Donna M O'Neil; Martin Bidlingmaier; Jeremy W Tomlinson; Zaki K Hassan-Smith; D Aled Rees; Christian Adolf; Stefanie Hahner; Marcus Quinkler; Tanja Dekkers; Jaap Deinum; Michael Biehl; Brian G Keevil; Cedric Hl Shackleton; Jonathan J Deeks; Axel K Walch; Felix Beuschlein; Martin Reincke
Journal:  JCI Insight       Date:  2017-04-20

9.  A Case of Adrenal Vein Sampling in Primary Aldosteronism With Homolateral Suppression.

Authors:  Andrea Viola; Silvia Monticone; Denis Rossato; Karine Versace; Isabella Castellano; Jacopo Burrello; Fabrizio Buffolo; Franco Veglio; Paolo Mulatero
Journal:  J Endocr Soc       Date:  2017-03-17

10.  Composite Cardiovascular Outcomes in Patients With Primary Aldosteronism Undergoing Medical Versus Surgical Treatment: A Meta-Analysis.

Authors:  Wei-Chieh Huang; Ying-Ying Chen; Yen-Hung Lin; Jeff S Chueh
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-17       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.